Basilea/Astellas change primary endpoint of Phase III trial of anti-fungal
This article was originally published in Scrip
Basilea Pharmaceutica and partner Astellas Pharma have agreed with the US FDA to change the primary endpoint of a Phase III trial investigating their broad-spectrum antifungal isavuconazole for the treatment of invasive aspergillosis, but said that the trial's timelines for completion remain unchanged from previous guidance of 2013 and also insisted that the efficacy hurdle has not been raised.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.